Home

Innovative veterinary medicine for better animal health

Through in-house research and pharmaceutical development, a growing product portfolio, and strong partnerships, Intervacc develops and provides veterinary vaccines and medicines that address key needs in animal health.

Our pipeline »

Technology »

Operations »

LATEST PRESS RELEASE: Intervacc to present at upcoming International Healthcare Conference »


LATEST REPORT:

Quarterly report Apr–Jun 2026

»


UPCOMING: AVEF Metz, France.»

Our veterinary vaccines and medicines



Strangvac®

Strangvac® is our proprietary modern vaccine against strangles, a highly contagious and serious equine disease caused by the bacterium *Streptococcus equi.* Read more »



Piggivac™

Development is underway of an innovative vaccine against infections caused by the bacterium *Streptococcus suis* – one of the most common causes of serious illness and mortality in pigs.Read more »




The product portfolio

In addition to our proprietary vaccine Strangvac®, we sell veterinary products for companion and farm animals in the Scandinavian markets. Read more »

FROM SCIENCE TO VETERINARY BENEFIT

Intervacc is a Swedish growth company in veterinary medicine




Healthcare
Digital Micro Cap Semina
Måndag 9 mars
INTERVACC


STOCKHOLM
CORPORATE
FINANCE
INTERVACC
Stockholm Corporate Fi
Life Science 2026
0:24

CURRENT PRESS RELEASES

View all »

15 Sep 2026
Intervacc to present at upcoming International Healthcare Conference»
20 Aug 2026
Interim Report January – June 2026»
30 Jul 2026
Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac»

IN THE CALENDAR

View all »

4 NOVEMBER 2026
AVEF Metz, France.
14 NOVEMBER 2026
VeTA Days, Upplands Väsby
Date Created
2026-09-10